Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction

dc.contributor.authorEPI Study Group
dc.contributor.authorHage, Chadi A.
dc.contributor.authorKlesney-Tait, Julia
dc.contributor.authorWille, Keith
dc.contributor.authorArcasoy, Selim
dc.contributor.authorYung, Gordon
dc.contributor.authorHertz, Marshall
dc.contributor.authorChan, Kevin M.
dc.contributor.authorMorrell, Matt
dc.contributor.authorGoldberg, Hilary
dc.contributor.authorVedantham, Suresh
dc.contributor.authorDerfler, Mary Clare
dc.contributor.authorCommean, Paul
dc.contributor.authorBerman, Keith
dc.contributor.authorSpitznagel, Ed
dc.contributor.authorAtkinson, Jeff
dc.contributor.authorDespotis, George
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-07-22T15:39:41Z
dc.date.available2024-07-22T15:39:41Z
dc.date.issued2021
dc.description.abstractBackground: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV1 in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. Study design and methods: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV1 decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. Results: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non-random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV1 decline that were reduced by 93% in evaluable ECP-treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV1 decline were observed in the non-survivors (-212 ± 177 ml/month) when compared to the survivors (-95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. Conclusions: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.
dc.eprint.versionFinal published version
dc.identifier.citationEPI Study Group, Hage CA, Klesney-Tait J, et al. Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction. Transfus Med. 2021;31(4):292-302. doi:10.1111/tme.12779
dc.identifier.urihttps://hdl.handle.net/1805/42362
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1111/tme.12779
dc.relation.journalTransfusion Medicine
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourcePMC
dc.subjectBronchiolitis obliterans syndrome
dc.subjectExtracorporeal photopheresis
dc.subjectForced expiratory volume in 1 s
dc.subjectLung transplantation
dc.titleExtracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Hage2021Extracorporeal-CCBYNCND.pdf
Size:
1.19 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: